Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Tentative Approval from The USFDA For Levomilnacipran Extended-Release Capsules
Details : Fetzima® generic version (levomilnacipran) is an oral extended release capsule which selectively inhibits serotonin and norepinephrine reuptake (SNRI) and it has shown positive results for the treatment of major depressive disorder (MDD) in adults.
Product Name : Levomilnacipran-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 16, 2023
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
